Display options
Cite
Saaby L, Tfelt-Hansen P, Brodin B. The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1. Pharmacol Res Perspect. 2015;3(4):e00151doi: 10.1002/prp2.151.
Saaby, L., Tfelt-Hansen, P., & Brodin, B. (2015). The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1. Pharmacology research & perspectives, 3(4), e00151. https://doi.org/10.1002/prp2.151
Saaby, Lasse, et al. "The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1." Pharmacology research & perspectives vol. 3,4 (2015): e00151. doi: https://doi.org/10.1002/prp2.151
Saaby L, Tfelt-Hansen P, Brodin B. The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1. Pharmacol Res Perspect. 2015 Aug;3(4):e00151. doi: 10.1002/prp2.151. Epub 2015 Jun 11. PMID: 26171231; PMCID: PMC4492727.
Copy Download .nbib Format: NLM
Share it on

Pharmacol Res Perspect. 2015 Aug;3(4):e00151. doi: 10.1002/prp2.151. Epub 2015 Jun 11.

The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1.

Pharmacology research & perspectives

Lasse Saaby, Peer Tfelt-Hansen, Birger Brodin

Affiliations

  1. Bioneer:FARMA, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup Hospital Glostrup, Denmark ; Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen Copenhagen, Denmark.
  2. Danish Headache Center, Department of Neurology, Glostrup Hospital, University of Copenhagen Glostrup, Denmark.
  3. Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen Copenhagen, Denmark.

PMID: 26171231 PMCID: PMC4492727 DOI: 10.1002/prp2.151

Abstract

Verapamil is used in high doses for the treatment of cluster headache. Verapamil has been described as a P-glycoprotein (P-gp, ABCB1) substrate. We wished to evaluate in vitro whether co administration of a P-gp inhibitor with verapamil could be a feasible strategy for increasing CNS uptake of verapamil. Fluxes of radiolabelled verapamil across MDCK II MDR1 monolayers were measured in the absence and presence of the putative P-gp inhibitor telmisartan (a clinically approved drug compound). Verapamil displayed a vectorial basolateral-to-apical transepithelial efflux across the MDCK II MDR1 monolayers with a permeability of 5.7 × 10(-5) cm sec(-1) compared to an apical to basolateral permeability of 1.3 × 10(-5) cm sec(-1). The efflux could be inhibited with the P-gp inhibitor zosuquidar. Zosuquidar (0.4 μmol/L) reduced the efflux ratio (PB-A/PA-B) for verapamil 4.6-1.6. The presence of telmisartan, however, only caused a slight reduction in P-gp-mediated verapamil transport to an efflux ratio of 3.4. Overall, the results of the present in vitro approach indicate, that clinical use of telmisartan as a P-gp inhibitor may not be an effective strategy for increasing brain uptake of verapamil by co-administration with telmisartan.

Keywords: Blood–brain barrier; P-glycoprotein; cluster headache; telmisartan; verapamil

References

  1. Neurology. 2000 Mar 28;54(6):1382-5 - PubMed
  2. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61 - PubMed
  3. Drug Metab Dispos. 2006 Dec;34(12):1976-84 - PubMed
  4. Pharm Res. 2013 Mar;30(3):847-56 - PubMed
  5. CNS Drugs. 2012 Jul 1;26(7):571-80 - PubMed
  6. Nucl Med Biol. 2013 Oct;40(7):873-8 - PubMed
  7. Drug Metab Pharmacokinet. 2014;29(1):101-4 - PubMed
  8. J Control Release. 2008 Jul 2;129(1):59-65 - PubMed
  9. J Pharmacol Exp Ther. 2001 Feb;296(2):450-7 - PubMed
  10. Int J Pharm. 2013 Jan 30;441(1-2):50-5 - PubMed
  11. Expert Opin Drug Metab Toxicol. 2010 Jul;6(7):863-71 - PubMed
  12. Cancer Res. 1996 Sep 15;56(18):4171-9 - PubMed
  13. J Pharmacol Exp Ther. 2000 May;293(2):376-82 - PubMed
  14. Drugs. 1998 Dec;56(6):1039-44; discussion 1045-6 - PubMed
  15. Expert Opin Pharmacother. 2010 Sep;11(13):2121-7 - PubMed
  16. Pharm Res. 1989 Jan;6(1):71-7 - PubMed
  17. Drug Metab Dispos. 2002 Apr;30(4):457-63 - PubMed
  18. Eur J Neurol. 2006 Oct;13(10):1066-77 - PubMed
  19. J Pharm Sci. 2003 Oct;92(10):1957-67 - PubMed
  20. Clin Pharmacol Ther. 2012 Feb;91(2):227-33 - PubMed
  21. Anticancer Res. 1995 May-Jun;15(3):811-4 - PubMed
  22. Neurology. 2007 Aug 14;69(7):668-75 - PubMed
  23. Lancet Neurol. 2004 Nov;3(11):645-51 - PubMed
  24. Headache. 2009 Jan;49(1):117-25 - PubMed
  25. EJNMMI Res. 2012 Oct 16;2(1):58 - PubMed
  26. Life Sci. 2010 Jan 2;86(1-2):52-8 - PubMed
  27. Clin Pharmacokinet. 2010 Apr;49(4):223-37 - PubMed
  28. Lancet Neurol. 2002 Aug;1(4):251-7 - PubMed
  29. J Pharm Sci. 1999 Jan;88(1):28-33 - PubMed
  30. Eur J Pharm Sci. 2006 Apr;27(5):543-54 - PubMed
  31. BMJ. 2012 Apr 11;344:e2407 - PubMed
  32. Eur J Biochem. 1994 Apr 1;221(1):363-73 - PubMed

Publication Types